A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
The CAR T-cell therapy bb2121 was granted breakthrough therapy designation by the Food and Drug Administration, speeding its review process.
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
Anticancer agents may be more active after transplantation than before, researchers suggested.
SAN FRANCISCO – The approach to relapsed/refractory multiple myeloma (MM) has to be tailored patient by patient based on the biology of the...
MADRID – Patients with refractory/relapsed multiple myeloma had similar rates of progression-free survival whether they were younger than age 65...
The use of pembrolizumab (Keytruda) in combination with dexamethasone and either lenalidomide or pomalidomide is associated with an increased risk...
An unusual case of orbital metastases, originating from multiple myeloma, challenges clinicians on diagnostic methods for proper treatment...